Prasugrel uncertainty weighs on Lilly shares
Uncertainty over when, or if, the U.S. Food and Drug Administration will approve prasugrel, a blood-thinner Eli Lilly and Co. hopes will be its next blockbuster, has taken a bite out of the company’s already slumping stock. Lilly shares closed Friday at $32.20, down $2.18, or 6.3 percent. It ticked up this morning, to $32.68, […]